Guadecitabine
As of the edition of 20 October 2026, Guadecitabine is a small molecule: stopped in 2023; acts on DNMT1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 33, 3 stopped early
- Disease areas
- Cancer; Blood and lymph; Urinary and reproductive; Pregnancy and women's health; Digestive system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Guadecitabine.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DNMT1 | DNA | P26358 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 5 | 3 | 0 |
| Phase 2 | 21 | 12 | 4 | 3 |
| Phase 3 | 3 | 3 | 0 | 0 |
| All trials | 33 |